Post Chief (NonCI) Massachusetts General Hospital

Jackson Distinguished Professor of Clinical Medicine Harvard Medical School

Honorary Physician Medicine-Nephrology, Massachusetts General Hospital

MD University of Pennsylvania 1971

behavioral research; clinical trials as topic; cyclic amp; disease prevention; epithelial biology; genetics; gtp-binding proteins; human genetics; kidney; membrane biology; receptors vasopressin; signal transduction; vasopressins; water channel regulation

Dennis Ausiello, MD is the Director of the Center for Assessment Technology and Continuous Health (CATCH), a program he founded as a joint effort between Massachusetts General Hospital and Massachusetts Institute of Technology (MIT) physicians, scientists and engineers to provide real-time measurement and analysis of the human phenotype in wellness and disease.

He previously served as Chief of Medicine at Mass General from 1996 until his retirement in 2013. In this role, he led one of the strongest departments of medicine in the country. He is a nationally recognized leader in academic medicine, having been elected to the Institute of Medicine of the National Academy of Science (1999) and the American Academy of Arts and Sciences (2003). He has written for many publications, including the New York Times and the Wall Street Journal, on various health subjects including human genetics, clinical trials, and the relationship between the academy and industry.

As an internationally recognized scientist, with specific expertise in epithelial and membrane biology, ion and water channel regulation and signal transduction, Dr. Ausiello has served as a council member of the National Institute of Diabetes, the Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging. 

He served on the Board of Directors of the Broad Institute, an independent partnership of Harvard and MIT faculty working in human genetics, as well as the board of directors of the nonprofit organization, Research!America, the leading advocate group for investment in biomedical research in the United States.